immune checkpoint inhibitor drugs

Anti-programmed cell death protein 1 (anti-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) monoclonal antibodies (mAbs) have revolutionized anticancer treatment. However, there are still many patients who do not respond or acquire resistance to these treatments. To overcome these limitations of therapeutic antibodies for immune checkpoints, Creative Biolabs offers immune checkpoint targeted small molecule drug development services to assist our customers with immune checkpoint research and drug development goals.

Learn more: immune checkpoint inhibitor drugs

最新文章

查看全部

iPSC Karyotype Analysis

The technology for creating induced pluripotent stem cell (iPSC) lines is a useful tool for research on development, regenerative medicine, and illness modeling. Long-term iPSC culture, however, leads

Anti-Glycan Antibody Engineering

Antibodies are a class of glycoproteins that the immune system naturally produces. They have defense properties against both internal and external antigens, and they are widely used in medicine for il

IVD Antibody Development Services for CD163 Marker

The CD163 gene encodes a protein known as cluster of differentiation 163 (CD163), which has a molecular weight of 130 kDa. It is the hemoglobin-haptoglobin complex's high-affinity scavenger receptor.